ArgenX tops BEL 20 on 'blue-sky scenario' Vyvgart progress
** Shares in ArgenX ARGX.BR rise 3.2% after the Belgian biotech company announced progress in the development of its flagship drug Vyvgart
** ArgenX said all three disease sub-types for Vyvgart Phase II/III ALKIVIA in myositis will advance to Phase III
** KBC Securities ("accumulate"), Van Lanschot Kempen ("buy") and JPMorgan ("overweight") all see the update as positive, the latter deeming it a "blue-sky scenario"
** JPM notes that positive myositis update "now clears they way for investors to play the Vyvgart CIDP launch upside thesis in 2025"
** Update shows strong proof-of-concept (POC) in myositis "in a broad sense", Van Lanschot Kempen says
** KBC updates its estimates, raises PT by 16% to 615 euros
** Shares, which are on track for their best day in three weeks, top Belgium's BEL 20 Index .BFX
Reporting by Olivier Cherfan
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
